Nifty
:
24734.30
Sensex
:
80718.01
19.25 (0.08%)
150.30 (0.19%)
Nifty
Sensex
:
:
24734.30
80718.01
19.25 (0.08%)
150.30 (0.19%)

Caplin Point Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 524742 | NSE: CAPLIPOINT

NSE BSE
2117.00
04-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  2180
  •  2180
  •  2105
  •  2161.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  38656
  •  82350313.1
  •  2641
  •  1599

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,067.73
  • 28.43
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 15,476.87
  • 0.28%
  • 5.53

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.56%
  • 0.95%
  • 14.32%
  • FII
  • DII
  • Others
  • 6.17%
  • 2.15%
  • 5.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.29
  • 12.79
  • 9.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.99
  • 14.81
  • 7.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 27.90
  • 17.23
  • 12.54

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.01
  • 20.72
  • 23.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.75
  • 4.46
  • 4.67

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.87
  • 15.01
  • 16.46

Earnings Forecasts:

(Updated: 04-09-2025)
Description
2024
2025
2026
2027
Adj EPS
70.67
80.93
96.23
P/E Ratio
29.96
26.16
22.00
Revenue
1937.47
2226.6
2610.05
EBITDA
646.93
746.4
893.1
Net Income
536.31
638.5
760.2
ROA
18.16
22.17
23.23
P/B Ratio
5.65
4.57
4.10
ROE
21.07
18.49
18.89
FCFF
291.96
439.57
467.42
2627.62
FCFF Yield
1.95
2.94
3.13
17.58
Net Debt
-897.72
1578.6
1481.7
BVPS
375.01
463.15
516.7

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
510.22
458.96
11.17%
502.45
453.22
10.86%
492.96
435.50
13.19%
483.10
410.06
17.81%
Expenses
332.46
307.15
8.24%
334.39
307.99
8.57%
330.67
293.22
12.77%
318.34
272.66
16.75%
EBITDA
177.76
151.81
17.09%
168.06
145.23
15.72%
162.29
142.28
14.06%
164.76
137.40
19.91%
EBIDTM
34.84%
33.08%
33.45%
32.04%
32.92%
32.67%
34.10%
33.51%
Other Income
23.14
18.56
24.68%
25.74
17.29
48.87%
31.36
17.18
82.54%
20.77
20.43
1.66%
Interest
0.18
0.05
260.00%
0.17
0.15
13.33%
0.18
0.17
5.88%
0.21
0.18
16.67%
Depreciation
16.29
15.96
2.07%
17.04
16.40
3.90%
16.20
13.90
16.55%
16.76
11.76
42.52%
PBT
184.43
154.36
19.48%
176.59
145.97
20.98%
177.27
145.39
21.93%
168.56
145.89
15.54%
Tax
33.70
29.46
14.39%
31.39
24.80
26.57%
37.19
25.59
45.33%
37.65
29.86
26.09%
PAT
150.73
124.90
20.68%
145.20
121.17
19.83%
140.08
119.80
16.93%
130.91
116.03
12.82%
PATM
29.54%
27.21%
28.90%
26.74%
28.42%
27.51%
27.10%
28.30%
EPS
20.11
16.31
23.30%
18.76
16.01
17.18%
18.28
15.43
18.47%
17.21
15.12
13.82%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
1,988.73
1,937.47
1,694.10
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
Net Sales Growth
13.14%
14.37%
15.50%
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
 
Cost Of Goods Sold
780.61
770.84
724.18
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
Gross Profit
1,208.12
1,166.63
969.92
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
GP Margin
60.75%
60.21%
57.25%
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
Total Expenditure
1,315.86
1,290.54
1,142.66
1,026.21
874.88
737.04
603.13
416.84
344.52
276.84
174.51
Power & Fuel Cost
-
37.83
33.57
25.53
21.40
16.36
14.81
13.76
10.98
9.91
7.56
% Of Sales
-
1.95%
1.98%
1.74%
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
Employee Cost
-
177.15
142.66
136.12
114.74
101.97
67.15
45.58
37.61
29.71
17.92
% Of Sales
-
9.14%
8.42%
9.28%
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
Manufacturing Exp.
-
120.13
117.73
90.99
82.01
69.85
68.23
43.49
37.11
28.56
14.33
% Of Sales
-
6.20%
6.95%
6.20%
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
General & Admin Exp.
-
112.05
92.97
85.38
66.68
38.53
25.50
20.82
12.27
13.78
8.15
% Of Sales
-
5.78%
5.49%
5.82%
5.25%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
Selling & Distn. Exp.
-
62.25
24.88
18.78
27.52
18.03
9.95
2.08
5.92
9.41
2.29
% Of Sales
-
3.21%
1.47%
1.28%
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
Miscellaneous Exp.
-
10.29
6.67
6.20
5.02
20.56
4.33
2.33
2.45
0.55
2.29
% Of Sales
-
0.53%
0.39%
0.42%
0.40%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
EBITDA
672.87
646.93
551.44
440.52
394.53
324.25
260.07
231.85
195.32
124.81
64.21
EBITDA Margin
33.83%
33.39%
32.55%
30.03%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
Other Income
101.01
96.43
66.94
56.52
38.89
27.93
41.33
19.03
12.67
9.96
3.66
Interest
0.74
0.61
0.78
0.78
0.70
1.59
0.32
0.58
0.61
0.52
0.34
Depreciation
66.29
65.96
53.44
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
PBT
706.85
676.79
564.16
451.27
385.82
313.62
269.46
226.88
188.38
120.95
60.05
Tax
139.93
135.69
103.01
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
Tax Rate
19.80%
20.05%
18.26%
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
PAT
566.92
536.31
457.09
376.26
299.84
242.27
215.00
176.56
144.78
95.61
45.77
PAT before Minority Interest
565.13
541.09
461.42
376.99
308.45
251.43
215.08
176.56
144.63
95.50
45.77
Minority Interest
-1.79
-4.78
-4.33
-0.73
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
PAT Margin
28.51%
27.68%
26.98%
25.65%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
PAT Growth
17.64%
17.33%
21.48%
25.49%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
 
EPS
74.59
70.57
60.14
49.51
39.45
31.88
28.29
23.23
19.05
12.58
6.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,850.49
2,315.71
1,880.48
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
Share Capital
89.78
89.77
89.76
89.74
89.71
89.71
51.05
15.12
15.12
15.11
Total Reserves
2,741.06
2,211.72
1,775.35
1,378.74
1,081.33
848.76
575.01
345.42
209.56
111.40
Non-Current Liabilities
13.24
7.89
2.13
12.55
17.39
24.86
23.42
27.86
19.90
13.69
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.02
0.29
0.32
0.48
0.73
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
1.74
9.04
7.78
8.48
5.69
5.23
0.13
0.00
0.40
1.63
Current Liabilities
305.99
330.85
268.00
207.68
142.85
144.32
86.11
108.67
113.36
125.04
Trade Payables
217.58
229.62
152.56
155.94
88.50
64.14
60.47
94.23
78.60
55.71
Other Current Liabilities
64.28
90.29
99.94
48.68
51.87
79.28
24.20
13.86
33.09
60.39
Short Term Borrowings
0.55
0.28
3.41
0.50
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
23.58
10.66
12.09
2.56
2.48
0.91
1.44
0.58
1.67
8.94
Total Liabilities
3,205.62
2,685.57
2,177.40
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
Net Block
545.78
452.66
279.81
286.57
305.34
272.50
226.84
169.48
151.83
144.23
Gross Block
859.52
702.31
480.32
445.74
422.58
354.79
271.51
231.79
195.15
180.76
Accumulated Depreciation
313.74
249.65
200.51
159.17
117.24
82.29
44.67
62.31
43.31
36.53
Non Current Assets
1,071.67
792.65
625.21
432.29
349.04
303.23
248.83
196.34
179.16
148.61
Capital Work in Progress
143.50
116.62
220.71
17.73
13.88
20.12
9.70
15.29
3.42
0.23
Non Current Investment
279.13
137.63
70.52
37.01
0.66
0.56
0.33
0.33
13.24
0.44
Long Term Loans & Adv.
88.61
78.31
51.51
89.90
7.92
10.05
11.95
11.23
10.67
3.71
Other Non Current Assets
14.65
7.43
2.66
1.08
21.24
0.00
0.00
0.00
0.00
0.00
Current Assets
2,133.95
1,892.92
1,552.19
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
Current Investments
311.33
237.98
210.18
51.97
10.54
60.23
69.62
46.34
4.20
0.00
Inventories
336.10
363.04
288.22
227.31
179.01
238.23
37.45
28.46
22.29
18.81
Sundry Debtors
632.49
542.72
394.06
317.05
279.36
228.96
159.81
125.88
33.02
7.95
Cash & Bank
591.41
552.74
493.48
462.99
438.33
223.43
152.99
79.28
93.07
68.10
Other Current Assets
262.62
50.43
22.82
13.61
107.33
71.68
73.83
24.16
26.63
23.67
Short Term Loans & Adv.
185.51
146.01
143.43
224.89
87.08
56.81
64.61
17.28
19.31
12.58
Net Current Assets
1,827.96
1,562.07
1,284.19
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
Total Assets
3,205.62
2,685.57
2,177.40
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
432.37
318.39
271.37
336.73
268.61
44.68
83.42
66.49
67.61
42.40
PBT
676.78
564.43
451.35
385.82
313.62
269.46
226.88
188.38
120.95
60.05
Adjustment
5.51
2.40
11.77
30.44
23.09
7.09
19.12
14.84
8.61
3.87
Changes in Working Capital
-122.28
-139.44
-103.75
1.96
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
Cash after chg. in Working capital
560.01
427.39
359.37
418.22
334.75
99.44
125.94
102.84
91.16
58.78
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-127.64
-109.00
-88.00
-81.49
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-334.73
-320.04
-217.58
-376.77
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
Net Fixed Assets
-55.85
-18.39
-56.57
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
Net Investments
-218.29
-99.00
-220.45
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
Others
-60.59
-202.65
59.44
-257.59
-40.57
16.68
-38.88
8.84
0.80
1.93
Cash from Financing Activity
-38.32
-38.07
-28.17
-40.68
-23.98
79.77
89.79
-11.60
-6.74
-13.95
Net Cash Inflow / Outflow
59.32
-39.72
25.62
-80.72
215.19
69.94
72.76
-14.13
24.76
22.73
Opening Cash & Equivalents
138.70
177.56
150.76
231.57
220.77
150.65
77.17
91.31
66.55
45.37
Closing Cash & Equivalent
193.74
134.20
170.92
150.76
435.72
220.77
150.65
77.17
91.31
68.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
362.67
293.21
235.91
183.89
144.94
114.21
78.03
47.69
29.73
16.25
ROA
18.37%
18.98%
19.30%
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
ROE
21.72%
22.97%
23.68%
24.77%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
ROCE
26.22%
26.92%
26.85%
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
Fixed Asset Turnover
2.48
2.87
3.17
2.92
2.73
2.76
2.58
2.53
2.14
1.48
Receivable days
110.70
100.92
88.48
85.74
87.41
82.19
80.37
53.72
18.62
10.40
Inventory Days
65.86
70.16
64.15
58.42
71.75
58.28
18.54
17.16
18.68
24.83
Payable days
105.88
96.31
84.89
80.02
59.05
28.33
65.76
89.68
88.17
103.48
Cash Conversion Cycle
70.68
74.76
67.73
64.14
100.11
112.15
33.15
-18.80
-50.88
-68.24
Total Debt/Equity
0.00
0.00
0.00
0.00
0.01
0.04
0.00
0.00
0.00
0.02
Interest Cover
1110.48
724.63
579.65
552.17
198.25
843.86
391.22
309.72
235.08
179.35

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Caplin Point’s arm gets USFDA’s final nod for Milrinone Lactate in 5% Dextrose Injection
    3rd Sep 2025, 16:14 PM

    Milrinone Lactate in 5% Dextrose Injection had US sales of around $11 million for the 12-month period ending July 2025

    Read More
  • Caplin Point Laboratories reports 23% rise in Q1 consolidated net profit
    7th Aug 2025, 15:36 PM

    The consolidated total income of the company increased by 11.69% at Rs 533.36 crore for Q1FY26

    Read More
  • Caplin Point Lab - Quarterly Results
    7th Aug 2025, 12:54 PM

    Read More
  • Caplin Point Laboratories’ arm executes SPA to acquire entire stake in Triwin Pharma
    4th Jun 2025, 15:41 PM

    Triwin Pharma’s object is to operate in Mexico in the Pharmaceutical Marketing and Distribution business

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.